Myriad COLARIS logo

 

COLARIS® is a genetic test that assesses a person’s risk of developing hereditary colorectal cancer and a woman’s risk of developing hereditary uterine (endometrial) cancer. Using a simple blood test or oral rinse sample, COLARIS® detects disease-causing mutations in the MLH1, MSH2, EPCAM, MSH6, PMS2 and MYH genes that are responsible for the majority of Lynch syndrome and MYH-associated polyposis (MAP) cases.

Myriad has developed a Hereditary Cancer Quiz that patients and physicians can use to help identify potential candidates for genetic testing using COLARIS.

COLARIS®: Hereditary Cancer Testing for Colorectal Cancer and Uterine (Endometrial) Cancer

Lynch syndrome, also known as Hereditary Nonpolyposis Colorectal Cancer (HNPCC) syndrome, is the most common of the hereditary colon cancer syndromes and is believed to account for three to five percent of all colorectal cancers. COLARIS® is a genetic test for Lynch syndrome. Knowing the results of the COLARIS® test may help patients and their healthcare professionals take steps to prevent cancer before it has a chance to develop.

MYH-associated polyposis (MAP) is caused by mutations in the MYH gene. Individuals with MAP have mutations in both of their MYH genes (one from each parent, often referred to as “biallelic MYH mutations”). Patients often have no family history of colon cancer or polyps in their parents (although siblings may be affected).1 The MYH gene is an important part of the base excision repair (BER) pathway, which allows for repair of DNA mutations caused by oxidative damage to cells.

Benefits of COLARIS® Testing

The results of the COLARIS® test enable patients and their healthcare professionals to develop individualized medical management plans to significantly reduce the risk of cancer.  COLARIS® helps healthcare professionals to:

  • Personalize patient care and increase clinical efficiency by targeting increased surveillance and other interventions specifically to individuals with the Lynch syndrome or MAP mutation(s);
  • Improve patient compliance with tailored screening recommendations and preventive measures;
  • Significantly improve outcomes and reduce medical costs through prevention, earlier diagnosis and treatment of cancer;
  • Counsel patients and family members on the underlying cause of cancer in their family; and
  • Avoid unnecessary interventions for family members who do not test positive for the mutation(s) known to be in the family.

Value of COLARIS hereditary cancer testing

Medical Management and COLARIS®*

Once a diagnosis of Lynch syndrome or MAP is confirmed, the following medical management options may help reduce the risk of cancer or detect it at an earlier, more treatable stage:

Colon Cancer (Lynch syndrome and MAP):

  • Increased surveillance for colorectal cancer
  • Surgical management of colorectal cancer

Uterine/Endometrial and Ovarian Cancer (Lynch syndrome):

  • Surveillance for endometrial and ovarian cancer
  • Surgical management of endometrial and ovarian cancer

Surveillance for Other Lynch Syndrome-Related Cancers:

  • Upper GI endoscopy, urinalysis, physical examinations

For more healthcare professional information, please visit MyriadPro.com.

*For medical management references, visit www.myriadpro.com/references
NOTE: Any discussion of medical management options is for general informational purposes only and does not constitute a recommendation.  While genetic testing and medical society guidelines provide important and useful information, medical management decisions should be made based on consultation between each patient and his or her healthcare professional.

References

1. Brand R, et al. MUTYH-Associated Polyposis. 2012 Oct 04. In: Pagon RA, et al., editors. GeneReviews® [Internet]. Available from http://www.ncbi.nlm.nih.gov/books/NBK107219/ PMID: 23035301